Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220009878IONIZABLE AMINE LIPIDS
US 13.01.2022
Int.Class C07C 229/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
229Compounds containing amino and carboxyl groups bound to the same carbon skeleton
02having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
04the carbon skeleton being acyclic and saturated
06having only one amino and one carboxyl group bound to the carbon skeleton
10the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
12to carbon atoms of acyclic carbon skeletons
Appl.No 17282157 Applicant Intellia Therapeutics, Inc. Inventor Rubina Giare Parmar

The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The ionizable amine lipids disclosed herein are useful as ionizable lipids in the formulation of lipid nanoparticle-based compositions.

2.WO/2022/007326METHOD AND USE FOR REAL-TIME FLUORESCENT PCR DETECTION OF CRONOBACTER SAKAZAKII O-ANTIGEN
WO 13.01.2022
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No PCT/CN2020/135549 Applicant NANKAI UNIVERSITY Inventor GUO, Xi
A method and use for real-time fluorescent PCR detection of Cronobacter sakazakii O-antigen, primarily utilizing a real-time fluorescent PCR reaction rapid detection system of an MGB probe to detect seven O-antigen serotypes of Cronobacter sakazakii. With Cronobacter sakazakii O1-O2-type and O4-O6-type wzy genes and O3-type and O7-type wzx genes as target genes, a Taqman specific primer and the MGB probe directed at each serotype are designed and screened, and a real-time fluorescent PCR detection method is established. The detection method accurately, rapidly, and sensitively performs molecular biology detection of all seven Cronobacter sakazakii O-antigen serotype strains.
3.WO/2022/007881MODIFIED GLUTAMATE DEHYDROGENASE AND USE THEREOF
WO 13.01.2022
Int.Class C12N 9/06
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
02Oxidoreductases (1.), e.g. luciferase
06acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
Appl.No PCT/CN2021/105179 Applicant SICHUAN LIER BIOTECHNOLOGY CO., LTD. Inventor XIE, Xinkai
Provided is modified glutamate dehydrogenase (GluDH). In particular, the modified GluDH provided has an improved activity of catalyzing PPO to react with an amino donor to generate L-glufosinate-ammonium and/or has an improved kinetic property. Further provided are a polynucleotide for encoding the modified GluDH, a vector and host cell for expressing the modified GluDH of the present invention, and a method for producing L-glufosinate-ammonium by means of using the modified GluDH and the host cell.
4.WO/2022/008466BASE EDITING TOOLS
WO 13.01.2022
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
Appl.No PCT/EP2021/068559 Applicant WAGENINGEN UNIVERSITEIT Inventor MOUGIAKOS, Ioannis
Thermostable, type II-C Cas9 variants of Geobacillus thermodenitrificans T12 (ThermoCas9) and Geobacillus stearothermophilus (GeoCas9) use 23 nt spacers to edit sites adjacent to an N4CVAA/N4CCCA or N4CRAA PAM, respectively. These Cas9 variants are linked to a cytidine deaminase enzyme from the sea lamprey Petromyzon marinus (PmCDA1) to provide: (a) dThermoTarget-AID, (b) dGeoTarget- AID, (c) AcrThermoTarget-AID, and (d) AcrGeoTarget-AID. Compared to known base editors, these systems exhibit much larger base editing windows: (a) from -5 to -27 positions relative to the PAM (23 bp); (b) from -5 to -24 positions relative to the PAM (20 bp); (c) from -5 to -27 positions relative to the PAM (23 pb); (d) from -3 to - 28 positions relative to the PAM (26 bp). The first two editors employ the catalytically inactive ThermoCas9 or GeoCas9, respectively, while the last two editors co-express a small anti-CRISPR protein from Neisseria meningitidis (AcrIIC1Nme) with active ThermoCas9 or GeoCas9, respectively. Methods of gene editing are described.
5.WO/2022/010761TDP-43 BIOSENSOR CELL LINES
WO 13.01.2022
Int.Class A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
Appl.No PCT/US2021/040238 Applicant THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM Inventor DIAMOND, Marc, I.
The present disclosure provides methods for the identification, characterization and ranking of putative tau monomer stabilizing agents. Specifically, the disclosure provides methods for assessing the capability of a test compound to stabilize a tau monomer, methods of prioritizing a plurality of test compounds from a library identified as tau monomer stabilizing agents, methods of screening a test compound library to identify tau monomer stabilizing agents, and a kit providing the reagents to perform the described methods.
6.WO/2022/011151MYBPC3 POLYPEPTIDES AND USES THEREOF
WO 13.01.2022
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/US2021/040906 Applicant CHILDREN'S MEDICAL CENTER CORPORATION Inventor PU, William, T.
Provided herein are compositions and methods for treating a disorder associated with abnormal RYR2 function (e.g., arrhythmia or heart failure). In some embodiments, method comprises administering to a subject in need thereof an effective amount of a polypeptide comprising a C -terminal domain of Cardiac Myosin binding protein C (MYBPC3) or a nucleic acid or an rAAV encoding such polypeptide.
7.20220007621ANIMAL MODEL OF MUCOPOLYSACCHARIDOSES TYPE IVA
US 13.01.2022
Int.Class A01K 67/027
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
67Rearing or breeding animals, not otherwise provided for; New breeds of animals
027New breeds of vertebrates
Appl.No 17293653 Applicant ESTEVE PHARMACEUTICALS, S.A. Inventor Maria-Fàtima BOSCH-TUBERT

The present invention provides a new animal model for mucopolysaccharidosis type lVA or Morquio A syndrome and to methods of generating the animal model and uses thereof.

8.WO/2022/006667DIAGNOSIS AND TREATMENT OF CHRONIC DIABETIC COMPLICATIONS USING LONG NON-CODING RNAS AS TARGETS
WO 13.01.2022
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/CA2021/050924 Applicant THE UNIVERSITY OF WESTERN ONTARIO Inventor CHAKRABARTI, Subrata
Method of identifying a subject as having an increased likelihood of progressing to end-organ damage due to diabetes comprising comparing the amount of a lncRNA in a sample from the subject with a reference value, and if the amount of the lncRNA in the sample is increased relative to the reference value, identifying the subject as having an increased probability of progressing to end-organ damage due to diabetes. The lncRNA is one or more of HOTAIR, H19, WISPER, ZFAS1, HULC, ANRIL, MALAT1, MIAT, and MEG3. Also methods of treating chronic diabetic complications and other conditions comprising administering a HOTAIR inhibitor.
9.WO/2022/007747PHOSPHORUS-EFFICIENT AND HIGH-YIELD GENE OF CROPS, AND APPLICATION THEREOF
WO 13.01.2022
Int.Class C12N 15/84
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
82for plant cells
84Ti-plasmids
Appl.No PCT/CN2021/104527 Applicant CAS CENTER FOR EXCELLENCE IN MOLECULAR PLANT SCIENCES Inventor HE, Zuhua
Provided are a phosphorus-efficient and high-yield gene of crops, and an application thereof. It is first disclosed that a PHO1;2 gene has a regulating function on filling of crop kernels. Up-regulating the expression of the gene in crops can significantly promote filling of the crop kernels, increase the kernel weight of the crop kernels, the kernels per spike, the tiller number and the kernel thickness, and/or promote thickening of the crops. The PHO1;2 gene plays a two-way phosphorus transport effect which mainly conveys phosphorus to the extracellular domain, can regulate intracellular phosphorus accumulation, increase the utilization rate of phosphorus in crops, and improve the duration of crops to a low-phosphorus environment.
10.WO/2022/007807BISPECIFIC ANTIBODY AND USE THEREOF
WO 13.01.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2021/104810 Applicant BIO-THERA SOLUTIONS, LTD. Inventor LIANG, Shizhong
Provided are a bispecific antibody and use thereof. The bispecific antibody or antigen binding fragment can bind to two antigens or two epitopes of the same antigen. The antibody or antigen binding fragment can be used for treating various diseases, such as inflammatory diseases, autoimmune diseases, cancer or spinal cord injury, and can also be used for the diagnosis and prognosis of related diseases.